Company Overview and News
The spotlight is again on the Parkinson’s Disease (PD) space this week. It has turned out to be an important focus area with Adamas Pharmaceuticals (ADMS - Free Report) launching its PD drug, Gocovri, and Pfizer (PFE - Free Report) dropping its plans to develop treatments for the indication. (47-0)
Acorda Therapeutics (ACOR - Free Report) announced that it has resubmitted the new drug application (NDA) for its late stage pipeline candidate, Inbrija, to the FDA. Following the news, shares of the company gained by about 1.9%. So far this year, shares of the company have increased 10.4% compared with the industry’s gain of 0.7%. (69-0)
Acorda Therapeutics, Inc. (ACOR - Free Report) recently announced that it is scrapping development of one of its lead Parkinson’s disease (“PD”) candidates, tozadenant. The decision was taken after some serious safety issues were observed in the phase III study, which was reported last week. (137-0)
Acorda Therapeutics, Inc. (ACOR - Free Report) announced that it has decided to immediately discontinue the phase III study on one of its lead Parkinson’s disease (“PD”) candidates, tozadenant. (99-0)
Additional data from a Phase 1 trial on Aducanumab has been reported this summer, while the drug is in Phase 3 testing. (349-1)
Acorda Therapeutics, Inc.'s (ACOR - Free Report) shares sank 40% on Wednesday after the company announced death of several patients in a late-stage study, evaluating one of its lead Parkinson’s disease (“PD”) candidates, tozadenant. (69-1)
If there is one cure or one treatment that could be the proverbial Holy Grail for a pharmaceutical or biotech company, it would be in a successful treatment of Alzheimer’s disease. This disease has ravaged an aging American population. More than 5 million Americans were already living with Alzheimer’s in 2014, and that number is expected to triple as the population continues to age. (372-2)
The "Electric Vehicles 2017-2037: Forecasts, Analysis and Opportunities" report has been added to Research and Markets' offering.
The "Global Huntington's Disease Therapeutics Market 2017-2021" report has been added to Research and Markets' offering.
Prana Biotechnology Limited (ASX:PBT, NASDAQ:PRAN) has executed a research collaboration with Takeda Pharmaceuticals International to study Prana’s lead movement disorders compound.
Shares in Prana Biotechnology (NADSAQ:PRAN) surged 19% and was earlier higher in New York as it said an article about early data on PBT434 had been accepted in a peer review journal.
Thinly traded Prana Biotechnology (PRAN +44%) continues its up move on an impressive 29x surge in volume. Shares have rallied almost 70% since trading resumed Tuesday.
With the aim of getting sign-off from regulators to initiate a Phase 3 clinical trial assessing lead product candidate PBT2 in Huntington's disease (HD), Prana Biotechnology (NASDAQ:PRAN) recently concluded meetings with the Medical and Healthcare Regulatory Agency in London and Medical Products Agency in Stockholm. Both recommended additional preclinical testing to establish the reversibility of the neurotoxicity observed in a dog study before considering a late-stage study in humans.
MELBOURNE, Australia--(BUSINESS WIRE)--Prana Biotechnology Ltd (ASX:PBT/NASDAQ:PRAN) is pleased to announce that further analysis of the cognitive results of its Reach2HD trial to treat Huntington Disease was presented in a poster1 at the American Neurological Association (ANA) Annual Meeting in Baltimore, United States.
WVE is pre-clinical; advanced programs are being studied to address Duchenne muscular dystrophy, Huntington’s disease, and inflammatory bowel disease (IBD).
2017-12-11 - Wilton
2017-12-11 - Wilton
2017-12-03 - Wilton
2017-11-27 - Wilton